160 related articles for article (PubMed ID: 8769188)
1. Oral cyclosporine preparations immediately following renal transplantation.
Katz SM; Amante A; Schoenberg L; Kahan BD
Transplant Proc; 1996 Aug; 28(4):2164. PubMed ID: 8769188
[TBL] [Abstract][Full Text] [Related]
2. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups.
Keown PA
Transplant Proc; 1996 Aug; 28(4):2147-50. PubMed ID: 8769183
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
Warrens AN; Salama A; Waters JB; Lechler RI
Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
Hoyer PF
Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
[TBL] [Abstract][Full Text] [Related]
7. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
[No Abstract] [Full Text] [Related]
8. Use of Neoral in pediatric renal transplantation.
Ettenger RE; Smith HT; Kaiser B; Cooney GF; Summerauer J; Alexander S; Moulton LT; Choc MG; Wong RL
Transplant Proc; 1996 Aug; 28(4):2257-8. PubMed ID: 8769217
[No Abstract] [Full Text] [Related]
9. Case study: de novo application of Neoral in renal transplantation.
Kahan BD
Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
[No Abstract] [Full Text] [Related]
10. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
Offermann G; Korn A
Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
[No Abstract] [Full Text] [Related]
11. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
[No Abstract] [Full Text] [Related]
12. Neoral pharmacokinetics in cynomolgus monkeys: relation to efficacy in renal allografting.
Schuurman HJ; Hengy JC; Ringers J; Vonderscher J; Schuler W; Jonker M
Transplant Proc; 1996 Dec; 28(6):3142-4. PubMed ID: 8962218
[No Abstract] [Full Text] [Related]
13. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
14. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
15. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients.
Stephan AG; Barbari A; Masri MA; Rizk S; Moubarak R; Frem GJ; Kamel G; Baracat-Khoury W; Karam A
Transplant Proc; 1996 Jun; 28(3):1348-9. PubMed ID: 8658688
[No Abstract] [Full Text] [Related]
17. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
Vathsala A; Lee WT; Jacob E; Woo KT
Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
[No Abstract] [Full Text] [Related]
18. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
[No Abstract] [Full Text] [Related]
19. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
Ritschel WA
Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation.
Kahan BD
Transplant Proc; 1996 Aug; 28(4):2143-6. PubMed ID: 8769182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
